JP2006520766A5 - - Google Patents

Download PDF

Info

Publication number
JP2006520766A5
JP2006520766A5 JP2006505151A JP2006505151A JP2006520766A5 JP 2006520766 A5 JP2006520766 A5 JP 2006520766A5 JP 2006505151 A JP2006505151 A JP 2006505151A JP 2006505151 A JP2006505151 A JP 2006505151A JP 2006520766 A5 JP2006520766 A5 JP 2006520766A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
therapeutic treatment
cancer
prophylactic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006505151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520766A (ja
JP4572194B2 (ja
Filing date
Publication date
Priority claimed from EP03290728A external-priority patent/EP1460076A1/en
Application filed filed Critical
Publication of JP2006520766A publication Critical patent/JP2006520766A/ja
Publication of JP2006520766A5 publication Critical patent/JP2006520766A5/ja
Application granted granted Critical
Publication of JP4572194B2 publication Critical patent/JP4572194B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006505151A 2003-03-21 2004-03-19 置換された8−パーフルオロアルキル−6,7,8,9−テトラヒドロピリミド[1,2−a]ピリミジン−4−オン誘導体 Expired - Fee Related JP4572194B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290728A EP1460076A1 (en) 2003-03-21 2003-03-21 Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
PCT/EP2004/004013 WO2004083210A1 (en) 2003-03-21 2004-03-19 SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2006520766A JP2006520766A (ja) 2006-09-14
JP2006520766A5 true JP2006520766A5 (https=) 2007-05-10
JP4572194B2 JP4572194B2 (ja) 2010-10-27

Family

ID=32799141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505151A Expired - Fee Related JP4572194B2 (ja) 2003-03-21 2004-03-19 置換された8−パーフルオロアルキル−6,7,8,9−テトラヒドロピリミド[1,2−a]ピリミジン−4−オン誘導体

Country Status (25)

Country Link
US (2) US7217715B2 (https=)
EP (2) EP1460076A1 (https=)
JP (1) JP4572194B2 (https=)
KR (1) KR101070075B1 (https=)
CN (1) CN100368412C (https=)
AR (1) AR053082A1 (https=)
AT (1) ATE433977T1 (https=)
AU (1) AU2004222105B2 (https=)
BR (1) BRPI0408605A (https=)
CA (1) CA2517774C (https=)
CY (1) CY1109345T1 (https=)
DE (1) DE602004021572D1 (https=)
DK (1) DK1608653T3 (https=)
EA (1) EA009198B1 (https=)
ES (1) ES2328812T3 (https=)
IL (1) IL170634A (https=)
MX (1) MXPA05010112A (https=)
NO (1) NO20054331L (https=)
NZ (1) NZ542224A (https=)
PL (1) PL1608653T3 (https=)
PT (1) PT1608653E (https=)
SI (1) SI1608653T1 (https=)
TW (1) TWI322809B (https=)
WO (1) WO2004083210A1 (https=)
ZA (1) ZA200507192B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460076A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
JP4277826B2 (ja) * 2005-06-23 2009-06-10 住友電気工業株式会社 窒化物結晶、窒化物結晶基板、エピ層付窒化物結晶基板、ならびに半導体デバイスおよびその製造方法
US8771552B2 (en) * 2005-06-23 2014-07-08 Sumitomo Electric Industries, Ltd. Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same
US9708735B2 (en) 2005-06-23 2017-07-18 Sumitomo Electric Industries, Ltd. Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP1790649A1 (en) 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1939187A1 (en) * 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
EP2138492A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138498A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138494A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138495A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
CN102482286B (zh) 2009-07-02 2015-07-15 赛诺菲 新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001270884A (ja) * 2000-03-23 2001-10-02 Mitsubishi-Tokyo Pharmaceuticals Inc ピリミドン誘導体
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1184383A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
AR030587A1 (es) * 2000-09-01 2003-08-27 Sanofi Aventis Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona
EP1460076A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives

Similar Documents

Publication Publication Date Title
JP2006520766A5 (https=)
JP2006519814A5 (https=)
JP2006520767A5 (https=)
GEP20115172B (en) Bicyclic cinnamide compound
EP2360165A3 (de) Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
IN2012DN02763A (https=)
JP2015501783A5 (https=)
JP2007504174A5 (https=)
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
TW200745135A (en) Therapeutic agents
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
PH12012502394A1 (en) Phosphaplatins and their use for treatment of cancers
JP2007516193A5 (https=)
JP2006519813A5 (https=)
WO2006058869A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
DE602005018634D1 (de) Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
JP2008526706A5 (https=)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2014141169A3 (en) Novel anti-neurodegenerative natural compounds isolated from alpiniae oxyphyllae fructus and total synthesis theirof
WO2006003523A3 (en) Human autism susceptibility gene encoding PRKCB1 and uses thereof
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
WO2006128268A8 (en) Ureidic compounds, pharmaceutical compositions containing the same and their use on the treatment of inflammatory diseases